Graphical Abstract Highlights d Glucose-derived pyruvate generates acetate in mammals d Two reaction mechanisms leading to acetate production are defined d Both mechanisms are coupled to mitochondrial function d Endogenous acetate can be required to maintain acetyl-CoA pools and lipogenesis In Brief Cells directly produce acetate from pyruvate through two distinct mechanisms, thus providing support for acetyl-CoA pools during times of metabolic deficiency.
INTRODUCTION
In conditions of hyperactive cellular metabolism, excessive cellular nutrient uptake results in incomplete metabolism and excretion of intermediates. The carbon source for catabolic and anabolic processes is often incompletely catabolized and excreted into the extracellular space (Meiser et al., 2018; Reaves et al., 2013) . During the Warburg effect, a phenotype characterized by increased glucose uptake, the glycolysis rate (near 100 mM/hr) is 10 to 100 times faster than the rate at which complete oxidation of glucose occurs in the mitochondria (Shestov et al., 2014) . As a result, the excess carbon from glycolysis is secreted as lactate. Other examples are seen in the cells in diabetic tissues, where excess fatty acid oxidation leads to incomplete lipid catabolism and excretion of acyl-carnitines and ke-tone bodies (Muoio, 2014) . Numerous other examples, such as in the case of excess anabolic substrates released in nucleotide synthesis or the excretion of formic acid during excess one carbon metabolism (Meiser et al., 2016) , are also apparent. In each case, overflow metabolism results from imbalanced metabolic supply and demand that results in limits to enzyme activity.
The products of these overflow pathways provide a valuable resource during conditions of nutrient limitation. Ketone bodies become fuel sources during fasting conditions, whereas lactate and alanine are readily metabolized in local microenvironments (Faubert et al., 2017; Sousa et al., 2016) . These unconventional fuel sources satisfy metabolic demands during nutrient scarcity. Interestingly, acetate is also a nutrient that has been found to be a major carbon source for central carbon metabolism in nutrient limited conditions. Acetate metabolism provides a parallel pathway for acetyl-coenzyme A (CoA) production separate from conversion of citrate to acetyl-CoA by ATP citrate lyase (ACLY) and thus acetate allows for protein acetylation and lipogenesis independent of citrate conversion to acetyl-CoA. This pathway is essential in nutrient-deprived tumor microenvironments and other diverse contexts, but the origin of acetate is unclear (Balmer et al., 2016; Comerford et al., 2014; Mashimo et al., 2014; Mews et al., 2017; Perry et al., 2016; Schug et al., 2015 Schug et al., , 2016 . It has been postulated that acetate may be synthesized de novo in cells (Andrae et al., 1985; Asmus et al., 2015; Bunton, 1949; Salahudeen et al., 1991; Vysochan et al., 2017) , but the pathways and quantitative reaction mechanisms through which this may occur are unknown. Given that alternative carbon sources often arise from overflow metabolism, we suspected that such a mechanism may allow for acetate generation. This hypothesis led us to conduct a re-evaluation of mammalian central carbon metabolism.
RESULTS
To monitor glycolysis in the setting of acetate metabolism, we incubated exponentially growing human colorectal HCT116 cells with uniformly labeled [ 13 C 6 ]-glucose, harvested metabolites over time, subjected the extracts to chemical derivatization with 2-hydrazinoquinoline (HQ) to capture acetate and other organic acids, and analyzed the products by liquid chromatography coupled to high-resolution mass spectrometry (LC-HRMS) ( Figure 1A ; STAR Methods). Monitoring the kinetics of [ 13 C 3 ]-pyruvate, [ 13 C 2 ]-acetate, and [ 13 C 3 ]-lactate unexpectedly revealed that the rates of generation of pyruvate and lactate, the end products of glycolysis, were commensurate with the rate of acetate generation (Figure 1B) . Strikingly, the concentration of [ 13 C 2 ]-acetate was comparable to the concentration of [ 13 C 3 ]-pyruvate and on the order of the amount of [ 13 C 3 ]-lactate generated from [ 13 C 6 ]-glucose in Figure 1 . Acetate Is Synthesized from Glucose Independent of Acetyl-CoA-Related Reactions (A) Scheme of experimental setup for measuring glucose-derived acetate, pyruvate, and lactate. (B) Medium concentration of [ 13 C 3 ]-pyruvate, [ 13 C 2 ]-acetate, and [ 13 C 3 ]-lactate secreted from HCT116 cells cultured in RPMI 1640 medium containing [ 13 C 6 ]-glucose. Medium was switched to the [ 13 C 6 ]-glucose medium at time 0. (C) The amount of [ 13 C 2 ]-pyruvate, [ 13 C 3 ]-lactate, and [ 13 C 2 ]-acetate released from various cultured cells at 40 min after switching to the [ 13 C 6 ]-glucose medium. (D) The relative levels of acetate production in HCT116 cells cultured in glucose-free medium containing different tracers: [ 13 C 6 ]-glucose (11.1 mM), [ 2 C 3 ]-lactate (5 mM), or [ 2 C 3 ]-pyruvate (5 mM). (E) Intracellular concentrations of metabolites in HCT116 cells after incubation in [ 13 C 6 ]-glucose medium for 5 hr. (F) Schematic depicting the workflow for HCT116 cells with [ 13 C 6 ]-glucose and/or treatment with the histone deacetylation inhibitor SAHA. (G) Western blots of histone acetylation sites from HCT116 cells in the absence or the presence of SAHA (5 mM) for 1 hr. (H) Ponceau S staining (left panel) and quantitative proteomic analysis (right panel) of histone extracts from HCT116 cells cultured in the presence of 13 C-glucose for 0, 6, 12 and 18 hr. An asterisk indicates 13 C-labeled acetyl groups on histones. (I) Release of acetate from HCT116 cells with a 6-hr pretreatment with [ 13 C 6 ]-glucose in the presence or the absence of histone deacetylation inhibitor (SAHA, 5 mM) for 1 hr (left panel). The release rate (right panel) is obtained by calculating the slope of the acetate release curve. Ac, acetate; Ac-histone, acetylated histone. The acetylated histone sites include lysine 14 (H3K14ac); lysine 18 (H3K18ac); lysine 18 and lysine 23 (H3K18acK23ac); lysine 23 (H3K23ac); lysine 27 (H3K27ac); lysine 9 (H3K9ac); lysine 9 and lysine 14 (H3K9acK14ac); lysine 14 containing mono-methylation at lysine 9 (H3K9me1K14ac); lysine 14 containing di-methylation at lysine 9 (H3K9me2K14ac); lysine 14 containing tri-methylation at lysine 9 (H3K9me3K14ac) of histone H3; and acetylation on lysine 16 (H4Kac), lysine 5 (H4K5ac), lysine 8 (H4K8ac), and lysine 12 (H4K12ac). Values are expressed as mean ± SD of n = 3 independent measurements. NS: p > 0.05 from a Student's t test. See also Figure S1. these glycolytic cells. De novo acetate production from glycolysis was also observed in several other cell lines of diverse origins (Figure 1C) . Indeed, there are other sources of pyruvate, such as alanine or lactate (Faubert et al., 2017; Sousa et al., 2016) . Thus, the presence of exogenous pyruvate or lactate also increased acetate production ( Figure 1D ). Meanwhile, switching the 13 C source from [ 13 C 6 ]-glucose to [ 13 C 5 ]-glutamine, which labels [ 13 C 3 ]-pyruvate to a far lesser extent, diminished the formation of [ 13 C 2 ]-acetate (Figures S1A and S1B). Together these findings suggest that acetate can be synthesized endogenously in quantitative amounts and with kinetics comparable to pyruvate and lactate production from glycolysis.
Acetate can be generated by the removal of acetyl groups from histones by histone deacetylases (Inoue and Fujimoto, 1969) and by hydrolysis of Ac-CoA (Knowles et al., 1974) . We thus measured the concentrations of the metabolites involved in these processes and observed orders of magnitude lower concentrations of Ac-CoA than glucose-derived pyruvate, lactate, and acetate ( Figure 1E ), suggesting that de novo acetate production likely is uncoupled from these acetyl-CoA dependent reactions. Moreover, the acetate HQ derivative was not spontaneously formed by incubating Ac-CoA or acetyl (Ac)-carnitine with the HQ derivatization reagents indicating this potential artifact is sufficiently controlled ( Figure S1C ). To further evaluate the contribution of deacetylation reactions, including histone deacetylation, to acetate production, we cultured HCT116 cells in [ 13 C 6 ]-glucose containing media for 6 hr, followed by incubation with the histone deacetylase inhibitor SAHA for an additional 1 hr ( Figure 1F ). Treatment with SAHA suppressed histone deacetylation ( Figure 1G ), indicated by the increase of total histone 3 acetylation (H3_ac) as well as acetylation of H3 on lysines 9 (H3K9ac) and 27 (H3K27ac) of histone H3. Furthermore, a quantitative proteomics analysis across a diverse set of acetylation sites revealed a consistent 60%-80% incorporation of [ 13 C 6 ]glucose at 6 hr that reached steady state ( Figure 1H ). [ 13 C 6 ]glucose medium was then replaced with 12 C glucose medium, and the release of [ 13 C 2 ]-acetate would represent the contribution from acetyl groups to acetate production. Histone deacetylase inhibition didn't alter the [ 13 C 2 ]-acetate release rate (Figure 1I) , and the measured [ 13 C 2 ]-acetate production rate from this assay was found to be nearly 5-fold less than the total amount ( 12 C and 13 C acetate) of acetate ( Figure 1I ), indicating that hydrolysis of the acetyl group from histones is not a major source of acetate in these experiments. Together, these experiments allow us to conclude that, in these conditions, more than 80% of the acetate measured is rapidly generated de novo through glycolysis.
It is generally thought that Ac-CoA formation requires glucose to first enter the mitochondria, be exported as citrate and then metabolized to cytosolic Ac-CoA ( Figure S1D ). Thus, we tested whether the pyruvate carrier inhibitor (UK5099) (Bricker et al., 2012; Divakaruni et al., 2013) that perturbs entry of pyruvate into the mitochondria would affect acetate generation. As expected, the 13 C-labeled Ac-CoA, Ac-carnitine (reversibly converted from Ac-CoA), and citrate (the first intermediate in the TCA cycle) were decreased by UK5099 treatment (Figures S1E-1G). Notably, no difference in the generation of [ 13 C 2 ]-acetate from [ 13 C 6 ]-glucose was observed ( Figure S1H ). Thus, these data indicate that acetate production is independent of Ac-CoA synthesis and breakdown.
One considerable possibility of a substrate for acetate production is pyruvate, a keto acid, that contains an electrophilic moiety. Keto acids have been reported to be chemical scavengers in both bacterial and mammalian cells (Kim et al., 2016; Wang et al., 2007) . A plausible reaction pathway for the generation of acetate could involve the nucleophilic attack of pyruvate by the reactive oxygen species generated from hydrogen peroxide (H 2 O 2 ) (Figure 2A, top) , and the reaction would involve incorporation of the oxygen into H 2 O 2 via production of superoxides and then into acetate. H 2 O 2 thus obtains oxygen from molecular O 2 and therefore, culturing cells in the presence of 18 O 2 and monitoring incorporation of 18 O into acetate would enable quantitation of the endogenous contribution of reactive oxygen species (ROS) to acetate production. In this experimental design, other potential acetate production routes (deacetylation or aldehyde oxidation) would involve transferring the oxygen in a water molecule to acetate. 18 O-labeled water is negligible in this setup, and thus these two possibilities could be resolved with this experiment (Figure 2A , bottom). We cultured cells in the presence of 20% O 2 ( 18 O 2 and 16 O 2 ) and 80% N 2 ( Figure 2B ). We then employed LC-HRMS to enable spectral resolution of [ 18 O 1 ]-acetate from other isotopically labeled species. We used labeled kynurenine (produced through oxygenation) in SKOV3 cells with high indoleamine-2,3-dioxygenase (IDO) expression (Litzenburger et al., 2014) to quantify the amount of heavy 18 O 2 experienced by the cells which was found to be about 40% in this setup ( Figure 2C ). We then identified ( Figure 2D ) and quantified ( Figure 2E) Figure 2E ). To further test this mechanism, inhibition of superoxide dismutase (SOD), which converts superoxides to H 2 O 2 ( Figure 2F ) , with tetrathiomolybdate (TTM), was done to decrease endogenous H 2 O 2 levels. Indeed, the presence of TTM decreased 18 O incorporation into H 2 O 2 -coupled reactions, including methionine sulfoxide ( Figure 2G ) and acetate ( Figures 2H and 2I ). These findings together demonstrate that endogenous H 2 O 2 contributes to acetate formation from pyruvate in cellular conditions.
To further investigate the properties of this reaction, we performed in vitro assays by incubating pyruvate with hydrogen peroxide at 37 C and found the major product to be acetate as measured by 1 H nuclear magnetic resonance spectroscopy (Figure S2A) . Thus, in the presence of hydrogen peroxide, pyruvate is converted to acetate non-enzymatically with kinetics commensurate with values needed for the reaction to occur at appreciable amounts in cells ( Figure S2B ). The reaction followed second order kinetics (k = 0.19 ± 0.05 mM À1 min À1 ) and could be accelerated with catalysts present in high concentrations in cells such as Cu 2+ , as Cu 2+ stabilizes the intermediate of pyruvate decarboxylation ( Figures S2B and S2C ).
As a further evaluation, we tested whether exogenous H 2 O 2 affects acetate production by adding [ 18 O 2 ]-H 2 O 2 to cultured HCT116 cells ( Figure 2J ). Titrating concentrations of [ 18 O 2 ]-H 2 O 2 revealed a dose-dependent increase in acetate levels, and the acetate detected had 18 O incorporation as measured by LC-HRMS ( Figure 2J ). Additionally, HCT116 cells pre-incubated with [ 13 C 6 ]-glucose and then treated with [ 18 O 2 ]-H 2 O 2 showed a transient increase in the amount of [ 18 O 1 ]-ace-tate peaking around 5 min post-induction of ROS with subsequent decay kinetics corresponding to the clearance of the ROS ( Figure 2J ) (Winterbourn, 2008 The presence of acetate unaccounted by isotopic labeling of oxygen suggests ROS-mediated pyruvate decarboxylation is not the only mechanism for de novo acetate production. Given that pyruvate is a keto acid, we next tested whether acetate can be released from keto acid dehydrogenases, considering that one function of this enzyme family is to catalyze the decarboxylation of the keto acid group. We first considered pyruvate dehydrogenase (PDH) ( Figure 3A ), which uses pyruvate as the substrate. Mammalian PDH mediates oxidative decarboxylation of pyruvate to acetyl-CoA. PDH is a multienzyme complex, containing three subunits (E1, E2, and E3). E1 catalyzes pyruvate decarboxylation using the cofactor thiamine pyrophosphate (TPP) and subsequent reductive acetylation of the lipoyl groups. E2 transfers the acetyl group to the thiol group in CoA and generates acetyl-CoA, and E3 regenerates the cofactor lipoate by coupling the oxidation to NAD + reduction. Therefore, the cofactors CoA and NAD + are required for PDH to achieve full activity. However, when CoA levels are lower than pyruvate levels, possibly, other thiol-containing molecules, such as glutathione (GSH) could serve as the acetyl group acceptor, considering that the cellular CoA is around 10 mM, whereas GSH is 1 to Figure 3B ), and similar concentration values in different types of cells or tissues were also reported by others Lee et al., 2014; Sadhukhan et al., 2016) . Low levels of CoA and high levels of GSH were also observed in autochthonous mouse tumors providing a physiological context for this occurrence ( Figure 3C ). Meanwhile, pyruvate was at much higher concentrations ( Figure 1E ). To study how these imbalanced substrate and cofactor concentrations affect PDH function, we incubated PDH isolated from porcine heart with [ 13 C 3 ]pyruvate in the presence or absence of cofactors (TPP, CoA, and NAD + ) ( Figure 3D ). Indeed, with CoA at saturated concentrations (400 mM), more than 99% of the pyruvate (200 mM) was consumed in less than 2 min ( Figure 3D) . Surprisingly, in the absence of CoA and NAD + , pyruvate was still consumed by PDH in the presence of TPP, but instead converted to [ 13 C 2 ]-acetate and [ 13 C 2 ]-acetaldehyde ( Figures 3D, 3E , and S3A), with lower overall PDH activity ( Figure S3B ). Furthermore, in the absence of CoA, GSH was found to be an acetyl group acceptor and increased overall PDH activity ( Figure 3E ) that resulted in the formation of [ 13 C 2 ]-acetyl-GSH (Ac-GSH) ( Figure 3E ). Interestingly, another keto acid dehydrogenase, alpha-ketoglutarate dehydrogenase (aKGDH), that normally catalyzes the conversion from alpha-ketoglutarate to succinyl-CoA via a similar mechanism as PDH, also functions as a pyruvate decarboxylase, catalyzing the conversion of pyruvate to acetaldehyde and to acetate ( Figures 3F and 3G ). Together, these data indicate that the release of intermediates as a result of incomplete oxidation, including acetate, acetaldehyde or acetyl-GSH, is regulated by the activity of keto acid dehydrogenases and the availability of cofactors CoA and NAD + ( Figure 3H ).
We then tested whether this also occurred in intact cells and mice. Indeed, [ 13 C 2 ]-acetate, [ 13 C 2 ]-acetaldehyde and [ 13 C 2 ]-Ac-GSH were quickly formed in HCT116 cells within a few minutes after [ 13 C 6 ]-glucose media were added ( Figure 4A ) and further confirmed with tandem mass spectrometry ( Figure S4A ). The intracellular concentration of [ 13 C 2 ]-acetaldehyde was found to be higher than the intracellular [ 13 C 2 ]-acetate concentration and also much higher than the concentration of [ 13 C 2 ]-acetaldehyde excreted into the media ( Figure 4B ). It is worth noting that the atmospheric boiling point of acetaldehyde and acetate is 20.2 and 118.1 C, respectively. Thus, acetaldehyde evaporated much faster than did acetate, and at 37 C, some of the acetaldehyde evaporates ( Figure S4B ). Therefore, intracellular acetaldehyde ( Figure 4B ) accumulated, whereas medium acetaldehyde evaporated, which suppresses, in part, the amount we are able to quantify. Production of acetate and Ac-GSH was decreased in cells engineered with CRISPR/Cas9 to lack PDH (Figures 4C and S4C). Interestingly, subcellular fractionation, followed by measurement of the levels of these dehydrogenases in the mitochondria and in the nucleus, indicated the quantitative presence of alpha-ketoglutarate dehydrogenase (aKGDH) in the nuclear fraction, whereas PDH is mostly in the mitochondria ( Figure 4D ). The presence of other keto acid dehydrogenases, such as aKGDH, prevented the complete depletion of de novo acetate production in PDH knockout (KO) cells ( Figure 4C ) and in cells treated with mitochondrial pyruvate carrier inhibitor UK5099 ( Figure S1H ). Therefore, thiamine deprivation was performed to inactivate both PDH and aKGDH by depleting thiamine pyro-phosphate. Thiamine deprivation for 4 days caused the depletion of thiamine, thiamine pyrophosphate (TPP), and alterations in the levels of TCA intermediates in HCT116 cells ( Figure S4D ), which is consistent with the hypothesis that thiamine depletion inactivates keto acid dehydrogenases (PDH and aKGDH). Consequently, thiamine depletion reduced acetate generation by more than 80% ( Figure 4E ), which is greater than the effects of PDH KO or treatment with UK5099. In addition, thiamine depletion also decreased ROS activity as evidenced by decreased ROS-mediated methionine sulfoxide formation and thus decreased the ROS-mediated acetate production (Figure S4E ). However, under thiamine starvation, the addition of exogenous ROS (H 2 O 2 ), especially in the presence of pyruvate in the medium greatly increased the contribution of ROS to acetate production ( Figures 4F, 4G, and S4F ). In addition, CPI-613, a lipoate analog and a PDH inhibitor, increased the formation of Ac-GSH ( Figure S4G ). Together, these results link thiamine pyrophosphate-dependent keto acid dehydrogenase activity to acetaldehyde, Ac-GSH, and acetate production, consistent with our findings using purified PDH enzyme ( Figure 3 ).
To determine whether these reaction mechanisms could occur in a physiological context, we first established a euglycemic transfusion system where mice ( Figure 3C ) bearing autochthonous sarcoma tumors were continuously infused with [ 13 C 6 ]glucose ( Figure 4H ; described in the STAR Methods). First, we conducted this experiment using tumor-free mice and observed that over 40% of the glucose in the serum at steady state could be labeled, resulting in approximately 32% [ 13 C 3 ]-pyruvate labeling ( Figure 4I ). Next, in tumor-bearing mice, both serum and tumor tissue were collected for metabolite analysis after 3 hr of glucose infusion. 13 C-labeled pyruvate, lactate, acetate, and acetaldehyde were detected in tumor tissue at different concentrations ( Figure 4J ). The enrichment of 13 C-labeled [ 13 C 2 ]-Ac-CoA and [ 13 C 2 ]-Ac-GSH was comparable ( Figure 4K ). The concentrations of [ 13 C 3 ]-pyruvate, [ 13 C 3 ]-lactate and [ 13 C 2 ]-acetate were much higher in the tumor than in the serum ( Figure 4L ), indicating that these metabolites were produced locally confirming our findings in vitro and in intact cells (Figures 3 and 4A-4G).
To expand the scope of the study and thus identify contexts in which this pathway is biologically necessary, we sought to explore situations in which acetate derived from some cells could interact with the metabolism of other cells. ATP citrate lyase (ACLY) is a cytosolic enzyme that converts nucleocytosolic citrate to Ac-CoA and acetate requirements in cells increase when its activity is impaired (Zhao et al., 2016) . We thus considered mouse embryonic fibroblasts (MEFs) that were engineered to lack ACLY (ACLY KO) (Figures 5A and 5B) that were previously described and further confirmed to exhibit an acquired dependence on acetate supplementation (Zhao et al., 2016) . Coculturing these MEFs with acetate-producing HCT116 cells separated by a 0.4-mm membrane allowing for free diffusion ( Figure 5C ) resulted in dramatically increased medium acetate concentrations in the MEF compartment ( Figure 5D ), and rescued deficiencies in the growth rate in the KO cells ( Figure 5E ) with negligible effects on the control (ACLY wild-type [WT]) MEFs ( Figure 5F ). ACSS2 is the enzyme that metabolizes acetate for acetyl-CoA production. As shown in Figures 5G and 5H , ACSS2 knockdown is detrimental to the fitness of MEF cells with ACLY deficiency, so the coculture time was shortened to 30 hr when ACSS2 knockdown cells were used, and the coculture with HCT116 cells ablated the rescue of cell proliferation. Consistent with prior findings (Zhao et al., 2016) , [ 13 C 6 ]-glucose contributed minimally to fatty acid synthesis in ACLY KO cells ( Figure 5I ). However, increased de novo lipogenesis indicated by increased incorporation of [ 13 C 6 ]-glucose into palmitate in ACLY KO cells cocultured with HCT116 cells confirmed increased cytosolic Ac-CoA production ( Figure 5I ). These findings demonstrate that endogenous de novo acetate produced through overflow metabolism from one cell type can be utilized to support proliferation of surrounding cells with acetyl-CoA insufficiencies ( Figure 5J ).
To further explore this pathway, we examined the effects of ACLY expression in high-acetate producing HCT116 cells cultured in [ 13 C 6 ]-glucose medium in the absence of acetate supplementation. ACLY knockdown had minor effects on de novo lipogenesis ( Figures 6A-6C) , whereas knockdown or inhibition using a small-molecule inhibitor (Comerford et al., 2014) of ACSS2 had larger effects on de novo lipogenesis ( Figures 6B  and 6C ) when no additional acetate was in the medium. The knockdown of both ACLY and ACSS2 reduced de novo lipogenesis to nearly undetectable amounts ( Figure 6B ). Furthermore, to evaluate the contribution of ROS-mediated acetate production to intracellular Ac-CoA pools, we measured the labeling patterns of surrogate products of Ac-CoA ( Figure 6D ), and we saw the incorporation of 18 O into Ac-carnitine ( Figure 6E ) and the increase in [ 13 C 2 , 18 O 2 ]-labeled acetylated molecules, including Ac-aspartate in the presence of UK5099 ( Figure 6F ). Nevertheless, the net effect was that lipogenesis is decreased by exogenous ROS and increased by the presence of catalase ( Figures S5A  and S5B ), which was likely attributed to the activity of lipogenesis enzymes also being affected by oxidative stress. Separately, the oxidation of amino acids, such as methionine, was suppressed in the presence of pyruvate due to the clearance of ROS by pyruvate via oxidative decarboxylation ( Figure S5C ). In addition, acetaldehyde, one of the intermediates released from incomplete oxidation of pyruvate, was oxidized to acetate by aldehyde dehydrogenase (Enomoto et al., 1991) and then subsequently supplied the Ac-CoA pool ( Figure 6G ). Isotope tracing with deuterated acetaldehyde confirmed that ACLY knockdown cells exhibited increased acetate utilization which could be further increased by limiting nutrient availability during serum starvation ( Figure 6H) , which is consistent with previous findings (Bulusu et al., 2017; Schug et al., 2015) . All together these experiments confirm that acetate generated from keto acid dehydrogenases or ROS-mediated pyruvate decarboxylation can have critical functional roles in supporting acetyl-CoA metabolism.
DISCUSSION
While it has been demonstrated that ACLY is required for histone acetylation in cancer cells, high ACLY activity is not necessarily a universal requirement for cellular acetylation events (Wellen et al., 2009) , indicating that acetate-derived acetyl groups could contribute to the cellular acetylation reactions. This is consistent with our observation ( Figure 6 ) that endogenous acetate production can support acetyl-CoA production for lipogenesis. In addition, the dependence on acetate to supply both nucleocytosolic (G) in HCT116 cells treated with control small interfering RNA (siRNA) or ACLY siRNA cultured in low (1%) or regular (10%) dialyzed FBS (H). Values are expressed as mean ± SD of n = 3 independent measurements. ND, not detected. **p < 0.001 from a Student's t test. See also Figure S5 . and mitochondrial acetyl-CoA pools has been identified in multiple cell types, including cancer cells, T cells, and neurons (Balmer et al., 2016; Comerford et al., 2014; Mashimo et al., 2014; Mews et al., 2017; Schug et al., 2015) . Our study provides evidence for a pyruvate-derived overflow pathway for acetate metabolism that occurs in mammalian cells. It further identifies two mechanisms with differential regulatory capacities involving non-enzymatic and enzymatic pyruvate-derived acetate chemistry. Thus, endogenous acetate production may be a fundamental component of mammalian central carbon metabolism.
One reaction mechanism found to generate acetate occurred through altered enzyme activity of thiamine-dependent keto acid dehydrogenases, which transformed their activity to keto acid decarboxylases. The availability of free CoA in the mitochondria is thought to limit the conversion of pyruvate to acetyl groups (Bremer, 1966) . It also has been demonstrated (Frey et al., 1989) that the absence of either CoA or NAD + causes the accumulation of hydroxyethyl-TPP (HETPP), which is the product of the E1 and the substrate of the E2 component. In addition, aKGDH and PDH are structurally and catalytically similar enzymes, given that the flavoprotein E3 components from PDH and aKGDH are identical (Reed, 2001) . It has also been reported that pyruvate is a substrate for aKGDH (Graham et al., 1989; Steginsky et al., 1985) . Interestingly, even though it has been thought that aKGDH is mainly located in mitochondria, the presence of nuclear aKGDH has been reported (Wang et al., 2017) and also supported by our data ( Figure 4D ). Therefore, although acetate production was depleted by thiamine starvation, neither PDH deletion nor mitochondrial pyruvate carrier inhibition alone was sufficient to completely remove acetate production. Thus, numerous pathways may exist by which acetate is coupled to other critical metabolic functions, depending on the activity and the location of keto acid dehydrogenases, the availability of cofactors.
The other reaction mechanism to generate acetate occurred by reaction with ROS, a finding which potentially links this pathway to numerous physiological and pathophysiological processes (Houstis et al., 2006; Sena et al., 2013) . 18 O 2 tracing and LC-HRMS allowed us to directly monitor ROS-mediated acetate production in intact cells without exogeneous ROS stimulation (Figure 1) , and the results suggest that oxidative stress could allow for coupling of acetate production to metabolic functions within central carbon metabolism (Dai et al., 2016; Murphy, 2009 ). ROS levels are dynamic and at steady state, intracellular concentrations of H 2 O 2 vary from nM to mM (Antunes and Cadenas, 2001; Chance et al., 1979) , whereas extracellular concentrations of H 2 O 2 may be 10 to 100 times higher under certain circumstances, such as inflammation (Test and Weiss, 1984) . Consistent with this pathway, cancer cells have been shown to produce H 2 O 2 at a rate of around 1 nmol/10 4 cells/hr (Szatrowski and Nathan, 1991; Weinstain et al., 2014) , whereas the combined pyruvate generation and secretion rate ( Figure 1B ) was found to be around 1 nmol/10 4 cells/hr. Under typical cell culture conditions, when PDH and aKGDH are active, ROS contributes to around 5%-15% of the acetate production ( Figure 2 ). However, thiamine deficiency is reported to be a common occurrence in cancer patients providing additional context (Isenberg-Grzeda et al., 2017; Onishi et al., 2017; Sechi et al., 2016) . Thiamine starvation and the addition of exo-geneous ROS greatly stimulated the ROS contribution to acetate production ( Figure 4G ), which can be used to replenish intracellular acetyl groups. Nevertheless, ROS can also impair the activity of certain proteins, such as those with active sites containing cysteine residues (van der Reest et al., 2018) . Because the amino acid residues of proteins are targets of ROS, and proteins have large sizes, many amino acid residues, and are present at high abundance (50%-70% of cell dry weight), which increase the reaction efficiency by increasing the likelihood of reactive collisions, especially when these protein residues are solventexposed. For such reasons, exogenous ROS increased ROSderived acetate production and the incorporation into cellular acetyl groups, but didn't cause a net increase in lipogenesis in cells subjected to ROS. Thus, increased acetate production and release could potentially favor the neighboring cells deficient in cytosolic acetyl-CoA, as demonstrated by coculturing ACLY KO cells with HCT116 cells ( Figure 5 ).
In addition, increased acetate production from ROS-mediated pyruvate decarboxylation suggests that pyruvate may naturally function as a ROS scavenger. Indeed, the presence of 1-5 mM pyruvate in typical cell culture media prevents the oxidation of methionine to methionine sulfoxide (as a marker of amino acid oxidation) ( Figure S5C ). Nevertheless, under certain conditions, ROS is known to play an important role in stimulating cell proliferation such as in T cell activation (Sena et al., 2013) , and we cannot rule out that under such conditions acetate production may possibly be related to ROS-stimulated cell proliferation.
Overall, our study elucidates pathways and quantitative reaction mechanisms through which pyruvate-derived de novo acetate production occurs. Moreover, our results reveal a potential role for de novo acetate production to supply acetyl groups and concomitantly, maintain lower cellular redox potentials. Although we have defined a set of biological examples that require this pathway, we have by no means defined the general biological role of these reactions. Thus, it would be of further interest to expand on the role of de novo acetate production in maintaining acetyl-CoA pools for the myriad biological settings that require acetyl groups.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture MEF (ACLY WT (Aclyf/f) and KO) cells were prepared as described previously (Zhao et al., 2016) . HCT116, SKOV3, HepG2, and BT474 cell lines were obtained from ATCC. The HeyA8 cell line was a generous gift from Dr. Ernst Lengyel's lab, University of Chicago, IL USA (Kenny et al., 2015) . Gender of the patients from whom the cell lines were derived: HCT116, male; SKOV3, female; BT474, female; HeyA8, female; HepG2, male. Mouse sarcoma cells were derived from sarcoma bearing male mice, and the procedure is described below. The original MEF cells were from male and female mixed mice. All human cell lines used in the study were authenticated at the Duke University DNA Analysis Facility using the GenePrint 10 kit (Promega) and tested to be mycoplasma-free. All cell culture related medium and reagents were sterilized using a 0.22 mm sterile filter. All cells were first cultured in a 10 cm dish with full growth medium (RPMI 1640 supplemented with 10% FBS). The cell incubator was set at 37 C supplemented with 5% CO 2 . For cell proliferation assays, cells were cultured in a 12 well plate, and at the end of treatment, cells were first harvested by trypsinization, and cell number and volume were measured using Moxi Z Mini Automated Cell Counter (ORFLO Technologies). For metabolite analysis, cells were seeded into 6 well plate at the density of 300 000 to 500 000 cells per well. After overnight incubation in full growth medium, for UK5099 treatment, the old medium was removed and cells were briefly washed with glucose free RPMI 1640 before 1.5 mL of RPMI 1640 (supplemented with 10% dialyzed FBS) with 0.025% DMSO or 5 mM UK5099 (final DMSO content 0.025%) was added to each well. After 5 hours of incubation, medium was replaced with 1 mL of RPMI 1640 containing 11.1 mM [ 13 C 6 ]-glucose, 10% dialyzed FBS, and 0.025% DMSO or 5 mM UK5099 (final DMSO content 0.025%). For acetate measurements, 5 mL medium from each well was collected at different time points and immediately placed on dry ice before storage in a À80 C freezer. Intracellular metabolites were extracted at 10, 20 and 40 min, and the detailed extraction procedure will be described below. directly added to each selected well (final concentration, 30 or 300 mM). 5 mL medium from each well was collected at 5, 10, 20 and 40 min. Intracellular metabolites were extracted at 30 min after addition of [ 18 O 2 ]-H 2 O 2 (300 mM). For CPI-613 treatment, HCT116 cells were incubated in RPMI 1640 (supplemented with 10% dialyzed FBS) in the absence or presence of 150 mM CPI-613 for 4 hours and media were replaced with 1 mL of RPMI 1640 containing 11.1 mM [ 13 C 6 ]-glucose, 10% dialyzed FBS, and 0.15% DMSO or 150 mM CPI-613 (final DMSO content 0.15%). Media were collected after 40 min, and intracellular metabolites were analyzed after a 1 hr incubation in 13 C-glucose media. For the thiamine deprivation assay, HCT116 cells were incubated in thiamine free RPMI 1640 (supplemented with 10% dialyzed FBS) for 4 days and media were replaced with 1 mL of thiamine free RPMI 1640 containing 11.1 mM [ 13 C 6 ]-glucose and 10% dialyzed FBS. Media and intracellular metabolites were collected after 40 min or 1hr incubation in 13 C-glucose media.
Animal
All animal procedures for this study were approved by the Institutional Animal Care and Use Committee (IACUC) at Duke University. 8 to 10-week old C57BL/6J male and female mixed mice (The Jackson Laboratory) were used to develop the 13 C-glucose infusion workflow. Mouse models of soft tissue sarcoma were generated in a mixed 129/SVJae and C57BL/6 background (The Jackson Laboratory) using a combination of alleles: Pax7 CreER-T2 , p53 fl/fl , LSL-Nras G12D . Primary mouse soft tissue sarcomas were generated in the mouse hind limb by intramuscular (IM) injection of (Z)-4-hydroxytamoxifen (4-OHT) . A euglycemic glucose infusion was performed according to a procedure previously described (Ayala et al., 2010) . Briefly, a jugular vein catheter was surgically implanted and exteriorized via a vascular access port, which allows infusion of [ 13 C 6 ]-glucose via the venous catheter. Blood from a tail nick in freely-moving and unanesthetized animals was serially withdrawn. Four to five days after surgery, mice were fasted for 6 hours and continuously infused with [ 13 C 6 ]-glucose at a rate of 20 mg/kg/min for a total of 3 hours. Blood was collected every 30 min for the duration of the infusion. Immediately following infusion, animals were sacrificed by cervical dislocation and liver tissue was excised and rapidly frozen in liquid N 2 to quench metabolism. Tissue was stored at À80 C until used for metabolite extractions.
No data were excluded from the analysis.
METHOD DETAILS
siRNA transfections siRNA transfection was performed following manufacturer's instructions with Lipofectamine RNAiMAX (Invitrogen), using siRNA pools targeting human ACLY (Dharmacon #L-004915-00), mouse ACSS2 (Dharmacon #L-065412-01), human ACSS2 (Dharmacon #L-010396-00) or a non-targeting control (Dharmacon #D-001810-10-20) at a concentration of 20 nM for ACLY and control, and 5 nM for ACSS2 in growth medium (RPMI 1640 with 10% FBS). After 48 hr, cells were split into a new 6 well plate in the absence of transfection reagents. All analysis (protein, metabolite and cell proliferation) was performed after 72 hr of siRNA transfections.
Western blotting
Whole cell lysates were prepared by collecting cells into ice cold RIPA buffer containing cOmplete Protease Inhibitor Cocktail (Roche). Protein lysate was first loaded to a NuPAGE 4%-12% Bis-Tris Protein Gels (Thermo Fisher Scientific) for separation, and then transferred to a PVDF membrane. The blot was visualized using ChemiDoc (Bio-Rad). Antibodies used are described in Key Resources Table. All antibodies were used at 1:1000 dilution.
Histone extraction for western blotting Cells were washed with ice cold PBS, supplemented with 5 mM sodium butyrate, and then collected in triton extraction buffer (TEB): PBS containing 0.5% (v/v) Triton X-100, 2mM phenylmethylsulfonyl fluoride (PMSF) and 0.02% (w/v) NaN 3 . After 10-min on ice with gentle stirring, the lysed cells were centrifuged at 2,000 rpm for 10 min at 4 C. The supernatant was removed, and the pellet was washed with half the volume of TEB and then resuspended in 0.2 N HCl. After acid extraction overnight at 4 C, the histone extract was centrifuged at 2,000 rpm for 10 min at 4 C. The supernatant was transferred to a new Eppendorf tube and protein concentration was determined by the Bradford assay. Aliquots were stored at À80 C until ready for blotting.
13
C labeling of histones HCT116 cells were seeded into 10 cm dish and cultured for 24 hours. The media were then replaced with labeling medium (RPMI 1640 glucose free medium supplemented with 11.1 mM [U-13 C]-glucose, and 10% dialyzed FBS). Histone extraction and sample preparation for LC-MS/MS analysis were performed as described below and previously (Lin and Garcia, 2012) . At the indicated time points, cells were washed with ice cold PBS (supplemented with 5 mM sodium butyrate), and then lysed in NIB-250 buffer (15 mM TrisCl pH 7.5, 60 mM KCl, 15 mM NaCl, 5 mM MgCl 2 , 1 mM CaCl 2 , 250 mM Sucrose), to which EDTA free cOmplete Protease Inhibitor Cocktail, sodium butyrate (final 5mM), DTT (final 1mM) and IGEPALâ CA-630 (NP-40, final 0.2%, v/v) were freshly added.
After allowing lysis to proceed on ice for 10 mins, nuclei were pelleted at 500 rcf. for 5 mins at 4 C, washed twice in NIB-250 buffer without detergent, and then extracted in 0.4 N H 2 SO 4 for 4 hr at 4 C with rotation. Insoluble debris was pelleted by centrifugation at 3 400 rcf. for 5 mins at 4 C and proteins were precipitated overnight on ice by adding 1 volume of trichloroacetic acid to 3 volumes of supernatant. Precipitated proteins were pelleted as above, washed with acetone containing 0.1% HCl and then pure acetone, and allowed to air dry before resuspending in 100 mM NH 4 HCO 3 .
Ponceau S staining was used to assess the purity of the histone extract. Histones were then derivatized with propionic anhydride (1 volume of 25% propionic anhydride in 2-propanol added to 2 volumes of histone peptides, incubated at 37 C for 15 mins, dried in a speed vac, and repeated) to block unmodified lysines and digested with trypsin. After trypsinization, histone peptides were derivatized with propionic anhydride again to add a propionyl group to the newly formed n-termini, desalted with C18 stage tips (Empore, 3M), and analyzed using LC-MS/MS as described below and previously (Lin and Garcia, 2012) . Peptides were separated online using an EASY-nLC (ThermoFisher Scientific) nano liquid chromatography system fitted with in-house pulled and packed C18 analytical columns (75 mm i.d. x 15-20 cm fused silica, 3 mm ReproSil-Pur 120 C18-AQ from Dr. Maisch GmbH). The gradient consisted of 5 to 33% B from 0 to 45 mins and 33 to 98% B from 45 to 50 mins, holding at 98% B until 60 mins with a flow rate of 300 nl/min, 0.1% formic acid in water serving as solvent A, and 80% acetonitrile with 0.1% formic acid serving as solvent B. Peptides were analyzed with an Orbitrap Fusion mass spectrometer (ThermFisher Scientific) operating in positive profile mode with the following full scan settings: 60 000 resolution, mass range 300-1100 m/z, AGC target 2e5, maximum injection time 100 ms. After one full scan in the orbitrap, eight data-independent acquisition (DIA) MS/MS scans of isolation width 50 m/z centered on 325. 4125, 375.4375, 425.4625, 475.4875, 525.5125, 575.5375, 625.5625, and 675 .5875 m/z were acquired in the ion trap in centroid mode, followed by another full scan, followed by another eight DIA MS/MS scans centered on 725. 6125, 775.6375, 825.6625, 875.6875, 925.7125, 975.7375, 1025.7625, and 1075 .7875 m/z. Mass range was set to 200-1500 m/z and quadrupole isolation set to on for DIA scans. HCD with NCE set to 30 was used for fragmentation with AGC target set at 1e4 and a maximum injection time of 50 ms. Mass spectra were analyzed by EpiProfile (Yuan et al., 2015) , which uses MS/MS spectra and chromatographic peak areas to quantify the abundance uniquely modified peptide species relative to sum of the modified and unmodified forms of a given peptide sequence.
Subcellular fractionation
For nuclei collection, around 10 7 cells were scraped into 1ml NIB-250 buffer containing protease inhibitor cocktail and 0.2% (v/v) NP-40, and kept on ice for 10 min with gentle pipetting. The lysates were centrifuged at 700 rcf. for 5 min at 4 C. The pellet (nuclei) was washed with 0.5 mL NIB-250 buffer without NP-40 and centrifuged. Intact mitochondria from HCT116 cells were obtained by using a Mitochondria Isolation Kit for Cultured Cells (ThermoFisher Scientific). Briefly, around 10 7 cells were scraped into 1ml hypotonic buffer provided by the manufacturer, and kept on ice for 6 min. A 2ml Dounce tissue grinder was then used to increase the lysis efficiency (around 80 strokes). The remaining steps were performed following the manufacturer's guidelines. The isolated nuclei and mitochondria were then lysed on ice for 30 min in RIPA buffer containing protease inhibitor cocktail with rigorous vortexing every 5 min. The lysates were centrifuged at 20 000 rcf. for 10 min at 4 C. The supernatant was used for protein concentration measurement by the Bradford assay. Aliquots were stored at À80 C until the time of the experiment.
HPLC method
Ultimate 3000 UHPLC (Dionex) was used for metabolite separation and detection. For polar metabolite analysis, a hydrophilic interaction chromatography method (HILIC) with an Xbridge amide column (100 3 2.1 mm i.d., 3.5 mm; Waters) was used for compound separation at room temperature. The mobile phase A: water with 5 mM ammonium acetate (pH 6.8); B: acetonitrile. Linear gradient: 0-1.5 min, 85% B; 5.5-10.5 min, 35% B; 10.6-12.5 min, 10% B; 13.5-19 min, 85% B. The flow rate was 0.15 ml/min from 0 to 5.5 min; 0.17 ml/min from 6.9 to 10.5 min; 0.3 ml/min from 10.6 to 17.9 min; and 0.15 ml/min from 18 to 19 min. 2-hydrazinoquinoline (HQ) derivatives were measured using a reversed phase LC method, which employed an Acclaim RSLC 120 C8 reversed phase column (150 3 2.1 mm i.d., 2.2 mm; Dionex) with mobile phase A: water with 0.05% formic acid, and mobile phase B: acetonitrile. Linear gradient: 0 min, 2% B; 3 min, 2% B; 8 min, 85% B; 9.5-14 min, 98% B; and 14.5-19 min, 2% B. Flow rate: 0.2 ml/min. Column temperature: 25 C.
Mass Spectrometry
The Q Exactive Plus mass spectrometer is equipped with a HESI probe, and the relevant parameters are as listed: heater temperature, 120 C; sheath gas, 30; auxiliary gas, 10; sweep gas, 3; spray voltage, 3.6 kV for positive mode and 2.5 kV for negative mode. Capillary temperature was set at 320 C, and S-lens was 55. When coupled with the HILIC method, a full scan range was set at 70 to 900 (m/z) with positive/negative switching except from 6.6 to 12.5 min, 100 to 1000 (m/z) in negative mode, and the resolution was set at 70 000 (at m/z 200). When coupled with reversed phase LC method, a full scan range was set at 170 to 800 (m/z) in positive mode, and the resolution was set at 140 000 (at m/z 200). The maximum injection time (max IT) was 200 ms at resolution of 70 000 and 450 ms at resolution of 140 000. High resolution mass spectrometry allowed for spectral resolution of isotopologues, such as [ 13 C 2 , 18 O 2 ]-Ac-carnitine from [ 13 C 4 ]-Ac-carnitine. Automated gain control (AGC) was targeted at 3 3 10 6 ions in full scan mode.
For targeted MS2 analysis, the isolation width of the precursor ion was set at 1.0 (m/z), high energy collision dissociation (HCD) was 35%, and max IT is 100 ms. The resolution and AGC were 35 000 and 200 000, respectively.
Metabolite extraction from cultured cells
For intracellular metabolite measurements, at different time points, the medium was removed, cells were briefly washed twice with 1 mL ice cold saline solution (0.9% NaCl in water) before placed on dry ice, followed by the addition of 1 mL 80% methanol/water (pre-cooled in À80 C freezer) to each well. After incubation in À80 C freezer for 15 min, cells were scraped into 80% methanol on dry ice and then transferred to Eppendorf tube. Samples were centrifuged at 20 000 g for 10 min at 4 C, and the supernatant was split into two Eppendorf tubes before drying in speed vacuum concentrator (Labcono). For absolute quantitation of GSH, CoA, Ac-CoA and Ac-carnitine, 13 C labeled E. coli metabolite extract or Ac-carnitine standard was added to the cell metabolite extract before drying. The dry pellets were reconstituted into 30 mL sample solvent (water:methanol:acetonitrile, 2:1:1, v/v) and 3 mL was injected into the LC-HRMS. The sample sequence of data acquisition was randomized. Figure S1 . Evaluation of the Effects of Glutamine and Pyruvate Carrier Inhibition on Acetate Production and the Levels of TCA Metabolites, Related to Figure 1 Figure S2 . Exogenous H 2 O 2 Catalyzes Pyruvate Decarboxylation to Acetate, Related to Figure 2 (A) Representative NMR spectra for pyruvate and acetate peaks from time 0 to 18.7 min. Time 0 min is when data acquisition began, and there is a delay from the actual reaction time due to temperature equilibration in the NMR tube. (B) Conversion rate of pyruvate (Pyr) to acetate under different conditions from 0 to 18.7 mins from the inception of the data acquisition. Conversion rate was calculated by dividing acetate peak area by the sum of acetate and pyruvate peak area. (C) Summary of reaction conditions, conversion rate (at 18.7 min), and reaction constant (mean ± SD). Figure S3 . Keto-Acid Dehydrogenases Catalyze Acetate and Acetaldehyde Production from Pyruvate, Related to Figure 3 Figure 6 (A and B) The relative levels of 13 C labeled fatty acid. HCT116 cells were first thiamine starved for 4 days, and then the old media were replaced with fresh media containing 100% [ 13 C 6 ]-glucose with or without catalase (600 U/ml). After incubation for 1hr, increasing doses of H 2 O 2 were added, and 1 hr after H 2 O 2 addition, free fatty acids were extracted from HCT116 cells. 
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